Author:
Hammond Catherine,Lieberman Jay Adam
Abstract
Purpose of review
Epinephrine is the first line treatment for anaphylaxis, however, there are limited data to support this. This review examines data surrounding evidence for the use of epinephrine in anaphylaxis, data on prescription for and use of epinephrine autoinjectors, and data examining newer routes of delivery of epinephrine; with a focus on recent publications over the past few years.
Recent findings
With recent epidemiologic studies of anaphylaxis and new forms of epinephrine being studied, new data on the effects of epinephrine are aiding in the understanding of epinephrine's effects and the shortcomings of epinephrine both in its effect and utility in the real world.
Summary
Epinephrine is still considered the first line therapy for anaphylaxis, and we are starting to have a better understanding of its effects in both healthy patients and those with anaphylaxis.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference49 articles.
1. Anaphylaxis: a 2023 practice parameter update;Golden;Ann Allergy Asthma Immunol,2024
2. EAACI guidelines: anaphylaxis (2021 update);Muraro;Allergy,2022
3. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis;Shaker;J Allergy Clin Immunol,2020
4. Epinephrine in anaphylaxis: too little, too late;Lieberman;Curr Opin Allergy Clin Immunol,2020
5. Optimal dose of adrenaline auto-injector for children and young people at risk of anaphylaxis: a phase IV randomized controlled crossover study;Patel;Allergy,2023